MTOR and hepatocellular carcinoma: Extensive preclinical data have pointed to an antitumor effect for mTOR inhibition in HCC [74], and a systematic review of 42 clinical studies involving 3,666 patients receiving a liver transplant for HCC found mTOR inhibition to be associated with a significantly lower rate of HCC recurrence versus CNI therapy (8% versus 13.8%, p < 0.001) [75].